Uniqure NV (QURE)

Currency in USD
13.680
-1.300(-8.68%)
Closed·
Pre Market
14.810+1.130(+8.26%)
·
QURE Scorecard
Full Analysis
3 analysts have revised their earnings upwards for the upcoming period
Unusual trading volume
Fair Value
Day's Range
12.33015.100
52 wk Range
4.45019.180
Key Statistics
Prev. Close
13.68
Open
14.74
Day's Range
12.33-15.1
52 wk Range
4.45-19.18
Volume
4.02M
Average Volume (3m)
1.52M
1-Year Change
75.27%
Book Value / Share
0.62
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
QURE Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
35.345
Upside
+158.37%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Uniqure NV News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Uniqure NV Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Compare QURE to Peers and Sector

Metrics to compare
QURE
Peers
Sector
Relationship
P/E Ratio
−3.4x−0.9x−0.5x
PEG Ratio
−0.120.000.00
Price/Book
22.2x3.2x2.6x
Price / LTM Sales
37.1x8.6x3.2x
Upside (Analyst Target)
114.1%202.1%42.0%
Fair Value Upside
Unlock29.1%6.6%Unlock

Analyst Ratings

11 Buy
2 Hold
0 Sell
Ratings:
13 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 35.345
(+158.37% Upside)

Earnings

Latest Release
Jul 29, 2025
EPS / Forecast
-0.69 / -0.89
Revenue / Forecast
5.30M / 5.40M
EPS Revisions
Last 90 days

QURE Income Statement

People Also Watch

15.83
SRPT
+14.21%
268.39
AVAV
-0.83%
23.22
OUST
-10.49%
60.26
MP
-6.01%
19.93
BEAM
-4.32%

FAQ

What Stock Exchange Does Uniqure NV Trade On?

Uniqure NV is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Uniqure NV?

The stock symbol for Uniqure NV is "QURE."

What Is the Uniqure NV Market Cap?

As of today, Uniqure NV market cap is 748.96M.

What Is Uniqure NV's Earnings Per Share (TTM)?

The Uniqure NV EPS (TTM) is -4.27.

When Is the Next Uniqure NV Earnings Date?

Uniqure NV will release its next earnings report on 28 Oct 2025.

From a Technical Analysis Perspective, Is QURE a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Uniqure NV Stock Split?

Uniqure NV has split 0 times.

How Many Employees Does Uniqure NV Have?

Uniqure NV has 209 employees.

What is the current trading status of Uniqure NV (QURE)?

As of 30 Jul 2025, Uniqure NV (QURE) is trading at a price of 13.68, with a previous close of 13.68. The stock has fluctuated within a day range of 12.33 to 15.10, while its 52-week range spans from 4.45 to 19.18.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.